News
Former Uber regional manager and Oscar Health COO has set out on her own to help busy people get help with their schedules by ...
The Global Women’s Health Market is expected to witness a growth rate of 4-5% in the next five years. Growing incidence of ...
Boston: Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to ...
Eli Lilly and Company witnessed a notable insider buy recently. David Ricks, the Chairman, invested a hefty $1.1 million in ...
To provide a brief background, the TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original ...
Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for beginners. On August 13, Cantor Fitzgerald ...
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.
The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results